Sparks commentary - Oryzon Genomics

Healthcare

Sparks - Oryzon Genomics

More on this equity
Oryzon (BME: ORY) publishes REIMAGINE results in prestigious journal
Published by Arron Aatkar, PhD

Oryzon Genomics has announced the publication of the final Phase IIa REIMAGINE results in the journal Psychiatry and Clinical Neurosciences. The REIMAGINE trial evaluated the safety and efficacy of lead CNS asset vafidemstat (an LSD1 inhibitor) in agitation/aggression in borderline personality disorder (BPD), attention-deficit/hyperactivity disorder and autistic spectrum disorder. Encouragingly, this study showed that vafidemstat could provide a clinical benefit in reducing agitation/aggression across all studied patient populations, forming the foundation for the company’s current lead CNS programme in BPD. The Phase IIb PORTICO trial demonstrated favourable results in this indication, and management is currently preparing for a potential Phase III programme. Vafidemstat is also being investigated in the Phase IIb EVOLUTION trial in negative symptoms of schizophrenia.

Latest

TMT | Comment

Pinewood (LSE: PINE) buys Seez

Industrials | Comment

Metlen (ASE: MYTIL) FY24 Results

Healthcare | Comment

GSK’s (LSE: GSK) five-in-one vaccine approved by the FDA

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free